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Abstract
Objective: The aims of this study were to establish the
structure of the potent anticonvulsant enaminone methyl
4-(4)-bromophenyl)amino-6-methyl-2-oxocyclohex-3-en-
1-oate (E139), and to determine the energetically pre-
ferred conformation of the molecule, which is responsi-
ble for the biological activity. Materials and Methods:
The structure of the molecule was determined by X-ray
crystallography. Theoretical ab initio calculations with
different basis sets were used to compare the energies of
the different enantiomers and to other structurally relat-
ed compounds. Results: The X-ray crystal structure re-
vealed two independent molecules of E139, both with
absolute configuration C11(S), C12(R), and their inverse.
Ab initio calculations with the 6-31G, 3-21G and STO-3G
basis sets confirmed that the C11(S), C12(R) enantiomer
with both substituents equatorial had the lowest energy.
Compared to relevant crystal structures, the geometry of
the theoretical structures shows a longer C–N and short-
er C=O distance with more cyclohexene ring puckering in
the isolated molecule. Conclusion: Based on a pharma-
cophoric model it is suggested that the enaminone sys-
tem HN–C=C–C=O and the 4-bromophenyl group in E139
are necessary to confer anticonvulsant property that
could lead to the design of new and improved anticon-
vulsant agents.
Copyright © 2003 S. Karger AG, Basel
Introduction 
Enaminones are a diverse group of compounds [1, 2]
exhibiting a range of pharmacological effects including-
cardiovascular [2], histaminergic [3], antimalarial [4], and
anticonvulsant activities [5–8]. The enaminone methyl 4-
(4)-bromophenyl)amino-6-methyl-2-oxocyclohex-3-en-1-
oate (E139), which contains two chiral centres, has been
shown to be a very potent anticonvulsant agent [7], but it
is not known which of the four possible enantiomers are
responsible for the activity of the compound. The aims of
this study were to determine the three-dimensional struc-
ture of E139 by X-ray crystallography, to compare this
structure with those calculated by ab initio quantum
mechanics using different basis sets, and to attempt to
predict the energetically preferred enantiomers. It is
hoped that these results will help in the design of more
potent anticonvulsant compounds.
D
ow
nl
oa
de
d 
by
: 
As
to
n 
Un
ive
rs
ity
-C
on
so
lid
at
io
n 
   
   
   
   
   
   
   
   
13
4.
15
1.
33
.1
68
 - 
11
/2
6/
20
14
 1
:2
9:
32
 P
M
238 Med Princ Pract 2003;12:237–242 Edafiogho/Denny/Schwalbe/Lowe
Table 1. Crystal data and structure
refinement for E139 Identification code e139babo
Empirical formula C30H32Br2N2O6
Formula weight 676.40
Temperature 293(2) K
Wavelength 0.71073 Å
Crystal system orthorhombic
Space group Pbca
Unit cell dimensions a = 8.8560 (10) Å · = 90 deg
b = 23.549 (2) Å ß = 90 deg
c = 28.867 (2) Å Á = 90 deg
Volume 6,020.2 (9) Å3
Z 8
Density (calculated) 1.493 mg/m3
Absorption coefficient 2.737 mm–1
F(000) 2,752
Crystal size 0.5 ! 0.4 ! 0.13 mm
Theta range for data collection 2.23–24.98 deg
Index ranges –4 ^ h ^  10, –27 ^ k ^ 5, 0 ^ l ^ 34
Reflections collected 5,845
Independent reflections 4,839 [R(int) = 0.0705]
Refinement method full-matrix least-squares on F2
Data/restraints/parameters 4,839/8/365
Goodness-of-fit on F2 0.853
Final R indices [I 1 2sigma(I)] R1 = 0.0667, wR2 = 0.1496
R indices (all data) R1 = 0.3489, wR2 = 0.2238
Largest difference peak and hole 0.457 and –0.386 e WA–3
Materials and Methods
Synthesis of E139 
The enaminone E139 was prepared and characterized according
to the methods of Scott et al. [7].
Anticonvulsant Evaluation of E139 
The anticonvulsant evaluation of E139 was carried out according
to previously reported procedures [7].
X-Ray Crystallography 
Repeated efforts at recrystallization of E139 yielded only weakly
diffracting material. The best specimen was obtained from ethanol as
a rectangular plate. Reflection data were measured by ˆ-2  scans at
rates as slow as 0.2 deg Wmin–1 on an Enraf-Nonius CAD4 diffractom-
eter equipped with a graphite monochromator using Mo K· radia-
tion (Ï = 0.71073 Å). The structures were solved by direct methods
with the SHELXS program and refined with absorption corrections
using SHELXL [9]. The features (approximately 0.5 e Å–3 or less) on
a final difference Fourier map were not significant. Molecular illus-
trations were drawn with the ORTEP program [10]. Experimental
details related to the structural analysis are provided in tables 1
and 2. Additional details of X-ray data are available upon request.
Theoretical Studies 
Ab initio quantum mechanical self-consistent field geometry
optimizations were carried out at the Hartree-Fock level without
constraints using STO-3G, 3-21G and 6-31G basis sets with gradient
convergence criteria of !0.001 Hartree/Bohr for the change in molec-
ular energy as a function of the three-dimensional atomic displace-
ment forces. All calculations were made with the ab initio package
GAMESS [11] on a cluster of Intel-based IBM systems fitted with
650 MHz CPUs. The compounds were visualized and geometry mea-
surements were made with the molecular modelling package CHEM-
X [12] on an IBM machine.
Results
Chemistry 
The enaminone E139 was obtained as a racemate with
a melting point of 188–190°C. Its UV data and elemental
(CHNBr) analyses supported the assigned structure [7]. It
has a molecular weight of 338.22 for the molecular formu-
la C15H16NO3Br, and a CLOGP value of 3.383. Proton
NMR spectroscopy [8] supported the chemical structure
of E139. The 1H NMR data were ‰ CDCl3 1.07 (3H, d, J =
5.88 Hz, CH3), 2.20 to 3.00 (3H, m, cyclohexene ring),
3.06 (1H, d, J = 11.37 Hz, cyclohexene ring), 3.72 (3H, s,
–OCH3), 5.46 (1H, s, = CH–), 6.97 to 7.18 (4H, m, C6H4),
7.29 (1H, bs, –NH–).
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Table 2. Atomic co-ordinates (!104) and equivalent isotropic dis-
placement parameters (A2 ! 103) for e139babo
x y z U(eq)
Br(1) 1,965(2) 721(1) 6,443(1) 95(1)
C(1) 2,398(14) 367(6) 5,876(4) 55(4)
C(2) 2,863(13) 705(5) 5,505(4) 59(3)
C(3) 3,124(13) 464(5) 5,082(4) 54(3)
C(4) 2,898(14) –124(4) 5,027(4) 49(3)
C(5) 2,566(14) –455(5) 5,399(4) 64(4)
C(6) 2,274(13) –203(5) 5,825(4) 63(4)
N(7) 3,207(10) –388(3) 4,588(3) 50(3)
C(8) 2,772(13) –211(5) 4,170(4) 42(3)
C(9) 1,850(13) 234(5) 4,083(4) 49(3)
C(10) 1,472(14) 400(5) 3,639(4) 55(4)
C(11) 2,102(18) 73(5) 3,238(4) 77(5)
C(12) 3,367(19) –324(6) 3,339(5) 101(6)
C(13) 3,280(15) –586(4) 3,775(4) 64(4)
C(14) 2,395(17) 442(6) 2,848(6) 100(7)
O(15) 3,300(13) 842(5) 2,891(4) 120(4)
O(16) 1,747(15) 382(5) 2,478(4) 154(6)
C(17) 2,260(20) 823(6) 2,086(5) 154(8)
O(18) 586(10) 799(3) 3,553(3) 68(2)
C(19) 3,826(16) –689(5) 2,928(4) 101(5)
Br(1)) 9,439(2) 1,917(1) 6,911(1) 111(1)
C(1)) 9,640(18) 2,259(5) 7,485(5) 70(4)
C(2)) 10,584(18) 2,711(5) 7,564(5) 81(4)
C(3)) 1,0691(15) 2,945(5) 7,988(5) 71(4)
C(4)) 9,925(15) 2,756(5) 8,363(4) 54(4)
C(5)) 8,931(15) 2,299(5) 8,294(5) 71(4)
C(6)) 8,814(16) 2,056(5) 7,859(5) 77(4)
N(7)) 10,051(10) 3,045(4) 8,791(3) 56(3)
C(8)) 10,130(13) 2,805(5) 9,216(4) 53(3)
C(9)) 10,368(13) 2,231(5) 9,297(4) 51(3)
C(10)) 10,341(14) 2,008(5) 9,734(4) 57(3)
C(11)) 9,934(15) 2,392(4) 10,139(4) 64(4)
C(12)) 10,152(18) 2,974(5) 10,067(4) 87(5)
C(13)) 9,952(13) 3,204(4) 9,612(4) 59(4)
C(14)) 10,147(17) 2,102(6) 10,575(5) 69(4)
O(15)) 11,389(13) 2,167(5) 10,767(4) 131(4)
O(16)) 9,089(14) 1,831(4) 10,738(4) 142(5)
C(17)) 9,660(20) 1,531(6) 11,213(4) 148(8)
O(18)) 10,686(9) 1,500(3) 9,828(3) 69(2)
C(19)) 9,669(14) 3,378(4) 10,463(4) 73(4)
U(eq) is defined as one third of the trace of the orthogonalized Uij
tensor.
Fig. 1. ORTEP [16] drawing of E139. The primed molecule has been
transformed by the c glide plane to show the hydrogen bond.
Pharmacology 
The enaminone E139 is a class 1 anticonvulsant in the
maximal electroshock test [7]. It had an anticonvulsant
activity in mice at a dose of 100 mg/kg intraperitoneally.
It protected rats against seizures at an oral dose of 50 mg/
kg without causing any neurotoxicity for periods up to 4 h.
In the rat, E139 had a TD50 of 270 mg/kg and an ED50 of
4 mg/kg affording a protective index of 167. Thus, E139
is a potent anticonvulsant enaminone.
X-Ray Crystal Structure of E139 
E139 crystallized from ethanol (table 1) showed two
independent molecules (fig. 1). Chains were formed by
hydrogen bonding between the NH and carbonyl oxygen
(O18) groups of unprimed and primed molecules in suc-
cession. Therefore, the three-dimensional structure of
E139 was determined by X-ray crystallography. The X-
ray data are listed in tables 1 and 2; table 2 gives the
atomic co-ordinates and isotropic displacement parame-
ters for non-hydrogen atoms.
Theoretical Calculations 
The mean differences in heavy atom bond lengths,
angles and torsions between the X-ray crystal structure
and the theoretical structures calculated using different
basis sets (6-31G, 3-21G and STO-3G) are summarized in
table 3. The best agreement is with the theoretical struc-
ture calculated with the 3-21G basis set. Table 4 presents
comparison of mean values of bond distances, bond
angles, and torsion angles relevant to the enaminone and
cyclohexene systems with those from the present crystal
structure and from theoretical calculation. The theoretical
structures show less delocalization in the enaminone moi-
ety leading to more pronounced alternation of bond dis-
tances, and a more sharply puckered cyclohexene ring.
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Table 3. Mean differences between bond lengths, angles and torsion
angles in crystal structure and theoretical structures (only non-hydro-
gen atoms in the molecule are considered)
6-31G 3-21G STO-3G
Bond lengths, Å 0.041 0.033 0.050
Bond angles, degrees 2.44 2.01 3.35
Torsion angles, degrees 7.42 6.43 7.55
Table 4. Selected bond lengths, bond angles, torsion angles: compar-
ison between average values in the crystal structure, average values in
the CSD, and ab initio optimized structure
a Bond lengths (Å)
Crystal CSD 3-21G
C4-N7 1.44 1.42 1.42
N7-C8 1.33 1.35 1.37
C8-C9 1.35 1.37 1.34
C9-C10 1.38 1.43 1.45
C10-O18 1.25 1.24 1.21
b Bond angles (°)
Crystal
(SU 1 °)
CSD
(SSD 1–2°)
3-21G
C4-N7-C8 127 127 128
N7-C8-C9 126 124 125
C8-C9-C10 123 122 123
C9-C10-O18 123 122 123
c Torsion angles (°)
Crystal CSD 3-21G
C4-N7-C8-C9 –5 (2) NM1 –5
N7-C8-C9-C10 179 (1) 177 180
N7-C8-C13-C12 –157, 1 157 –161
C8-C9-C10-C11 0, 2 4 11
C8-C9-C10-O18 178, 1 177 –170
C9-C10-C11-C12 –14, 2 25 –39
C10-C11-C12-C13 34, 2 48 56
C11-C12-C13-C8 –41, 2 48 –47
C12-C13-C8-C9 28, 2 25 21
Standard uncertainties (SU) in the crystal structure and sample
standard deviations (SSD) from the CSD are 0.01–0.02 Å.
Because averaging is inappropriate, both independent molecules
are given (SU 1–2°). Since two different sequences of signs arise in
the CSD, absolute values have been averaged (SSD from 2° for N7-
C8-C9-C10 to 11° for C10-C11-C12-C13 and C11-C12-C13-C8).
1 Not meaningful because values cluster around both 0° and 180°.
Table 5. Energies (in kJ/mol) of the enantiomers of E139 relative to
the most stable enantiomer calculated using different ab initio basis
sets
6-31G 3-21G STO-3G
C11(S ), C12(R ) 0.00 0.00 0.00
C11(R ), C12(R ) 5.02 3.34 1.73
C11(S ), C12(S ) 11.79 8.47 5.77
C11(R ), C12(S ) 8.82 4.60 4.27
Atom numbering is taken from figure 1 (ORTEP drawing).
The relative energies of the different enantiomers of
E139 optimized by different ab initio methods are given
in table 5. The results indicate that the lowest energy
enantiomer is the C11(S), C12(R) form with substituents
equatorial, as observed in the X-ray crystal structure. Oth-
er enantiomers were generated by interchanging a substit-
uent and a hydrogen atom on C11 and/or C12, and thus
have one or more axial substituents. The rank order of
their energies is the same for all three basis sets used for
the calculations.
The absolute configuration of the molecule is C11(S),
C12(R) (atom numbering based on the ORTEP drawing);
their centrosymmetric images are also present. The angles
between phenyl and enaminone planes are 48.0(6)° and
52.6(6)°, respectively, and bond lengths confirm that N7
is more closely integrated into the enaminone  system.
Every bond angle in the enaminone moiety is expanded
above 120° (table 4b). The cyclohexene ring occurs in a
twisted half-chair shape with torsion angles in the ring dif-
fering by up to 24°, presumably due to crystal packing
forces. An analogous structure with two very different
degrees of puckering in the cyclohexene rings has pre-
viously been reported [13].
Discussion
Theoretical Calculations 
Enaminones in the crystalline state are subject to dis-
tortions that do not affect the isolated molecule. Although
electron donation from N to O atoms always shortens the
C–N bond and lengthens C=O, this effect is exaggerated
by resonance-assisted hydrogen bonding [14]. Sometimes
a cyclohexene ring is found in an almost ideal sofa confor-
mation [15], but other reported structures differ greatly
from it. A search of the Cambridge Structural Database
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(CSD) [16] with 3-(secondary amino)-cyclohex-2-ene-1-
one as the search group, no other fused ring, and R !0.1
revealed 26 independent molecules.
The theoretical results shown are for gas phase calcula-
tions, and the energetic preference for enantiomer and
conformation could change in solution. However, NMR
evidence indicates that a single species is formed. This is
consistent with work on other enaminones where a single
enantiomer is formed about a chiral position on the cyclo-
hexene ring [13].
Structural Requirements for Anticonvulsant Activity of
E139 
In the high field 1H NMR spectrum, the amino tau-
tomer was predominant, and no evidence for the imino
tautomer was found. The vinyl proton at ‰ 5.46 indicated
that the double bond in the enaminone system was a C=C
of the amino tautomer, and not a C=N of the imino tau-
tomer. If the imino tautomer existed to any significant
extent, one would observe the methylene (CH2) protons
about ‰ 2.50, and the vinyl proton signal would be dimin-
ished. The amino tautomer [8] was confirmed by the X-
ray crystallography of E139.
Using the putative binding site theory proposed by
Dimmock et al. [17] and utilized by Pandeya et al. [18] in
postulating the interaction of anticonvulsant compounds
at a specific binding site, it would appear that the enami-
none E139 fits the criteria for a good lead compound. This
theory proposes that anticonvulsant compounds interact
at two locations at the binding site. These are designated
the hydrogen bonding and the hydrophobic bonding ar-
eas. In the absence of an identified binding site, it was
assumed that the hydrogen bonding area was a peptide
chain whereby the repeating amidic functions allow hy-
drogen bond formation. We suggest that the pharmaco-
phoric descriptors for E139 are the 4-bromophenyl group
being complementary to the hydrophobic bonding area,
and the enaminone system HN–C=C–C=O being comple-
mentary to the hydrogen bonding area (fig. 2). To achieve
the suggested hydrogen bonding, the enaminone C=C
bond must be cis to the N–H bond, not the N-phenyl bond
as in the crystal structure. Among other enaminone sys-
tems incorporating an anilino substituent, four crystal
structures do exhibit the required cis relationship between
C=C and N–H.
The heteroconjugated enaminone system HN–C=C–
C=O in E139 would form resonance-assisted hydrogen
bonds [14], and intermolecular bonds can give rise to
infinite molecular chains called catemers. The cyclohex-
ene ring holds the enaminone system in a fixed conforma-
Fig. 2. Proposed interactions of enaminone E139 at a binding site
[adapted from ref. 17].
NH
O
CH R
NH
CO
C RH
NH
C O
CHR
NH
N
Br
O
H
C
OCH
3
H
3
C
H
O
Hydrophobic bonding area
Hydrogen bonding area
C
tion, and theoretical ab initio calculations confirmed that
the C11(S), C12(R) enantiomer with both substituents
equatorial had the lowest energy. The previously men-
tioned researchers have indicated that the 4-bromophenyl
moiety fulfilled the structural requirements for binding at
the hydrophobic binding site [17, 18]. Similarly, the 4-
bromophenyl group and the enaminone system in E139
satisfy the structural requirements for interaction at a
putative binding site for anticonvulsant compounds.
Conclusion 
The E139 enaminone has been shown to have desir-
able anticonvulsant property. It is not neurotoxic in rats
at an oral dose of 50 mg/kg and can be a lead compound
for further molecular modification that will result in more
potent anticonvulsant agents.
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